

5367.230-US
October 22, 2004

Application Number 10/730,215
Page 2 of 7

AMENDMENTS TO THE CLAIMS

The following Listing of Claims replaces all prior versions, and listings, of claims in this Application.

LISTING OF CLAIMS

1-3 (cancelled)

4. (presently amended) A method of promoting the treatment of ~~small bowel syndrome, Crohn's disease, ileitis, intestinal inflammation, gastric ulceration, duodenal ulceration, inflammatory bowel disease, or~~ intestinal cancer damage therapy in a patient comprising administering an effective amount of a pharmaceutically acceptable composition comprising (a) a non-naturally occurring polypeptide having an amino acid sequence according to the formula X1 H X2 D G S F S D E M N T X3 L D X4 L A X5 X6 D F I N W L X7 X8 T K I T D X9 (SEQ ID NO: 1) and (b) a pharmaceutically acceptable combination of (i) an isotonic agent, (ii) a buffer, and (iii) a preservative, a surfactant, or a combination of a surfactant and a preservative, wherein (I) X1 is NH₂, DFPEEVAIVEELGRR (SEQ ID NO:2), DFPEEVTIVEELGRR (SEQ ID NO:3), DFPEEVNIVEELRRR (SEQ ID NO:4), or a fragment of any of SEQ ID NOS:2-4; X2 is Ala or Gly; X3 is Ile or Val; X4 is Asn, Ser, or His; X5 is Ala or Thr; X6 is Arg or Lys; X7 is Ile or Leu; X8 is Gln or His; and X9 is OH, Lys, Arg, Arg-Lys, Lys-Arg, Arg-Arg, or Lys-Lys and (II) the solubility of the peptide, stability of the peptide, or both is significantly greater than the solubility

5367.230-US
October 22, 2004

Application Number 10/730,215
Page 3 of 7

and/or stability of the peptide without the combination the composition of claim 2 to the patient.

5. (presently amended) The method of claim 4, wherein X2 represents Gly A method of promoting the treatment of small bowel syndrome, Crohn's disease, ileitis, intestinal inflammation, gastric ulceration, duodenal ulceration, inflammatory bowel disease, or intestinal cancer damage therapy in a patient comprising administering an effective amount of the composition of claim 3 to the patient.

6-9 (cancelled)

10. (presently amended) A method of promoting the treatment of ~~small bowel syndrome, Crohn's disease, ileitis, intestinal inflammation, gastric ulceration, duodenal ulceration, inflammatory bowel disease, or intestinal cancer damage therapy in a patient comprising administering an effective amount of the peptide of claim 6~~ a non-naturally occurring polypeptide having an amino acid sequence according to the formula X1 H X2 D G S F S D E M N T X3 L D X4 L A X5 X6 D F I N W L X7 X8 T K I T D X9 (SEQ ID NO: 1), wherein (I) X1 is NH2, DFPEEVAIVEELGRR (SEQ ID NO:2), DFPEEVTIVEELGRR (SEQ ID NO:3), DFPEEVNIVEELRRR (SEQ ID NO:4), or a fragment of any of SEQ ID NOS:2-4; X2 is Ala or Gly; X3 is Ile or Val; X4 is Asn, Ser, or His; X5 is Ala or Thr; X6 is Arg or Lys; X7 is

5367.230-US
October 22, 2004

Application Number 10/730,215
Page 4 of 7

Ile or Leu; X8 is Gln or His; and X9 is OH, Lys, Arg, Arg-Lys, Lys-Arg, Arg-Arg, or Lys-Lys to the patient.

11. (presently amended) The method of claim 10, wherein X2 represents Gly ~~A method of promoting the treatment of small bowel syndrome, Crohn's disease, ileitis, intestinal inflammation, gastric ulceration, duodenal ulceration, inflammatory bowel disease, or intestinal cancer damage therapy in a patient comprising administering an effective amount of the peptide of claim 7 to the patient.~~

12. (new) The method of claim 10, wherein the composition comprises a preservative.

13. (new) The method of claim 12, wherein the composition comprises a surfactant.

14. (new) The method of claim 4, wherein the method comprises reconstituting a lyophilized composition comprising the non-naturally occurring polypeptide and preparing the pharmaceutically acceptable composition prior to administering the pharmaceutically acceptable composition to the patient.

15. (new) The method of claim 10, wherein the method comprises reconstituting a lyophilized composition comprising the non-

5367.230-US
October 22, 2004

Application Number 10/730,215
Page 5 of 7

naturally occurring polypeptide prior to administering the polypeptide to the patient.